Modulation by dopamine receptors of the histamine release in the rat hypothalamus. 1993

H Prast, and M Heistracher, and A Philippu
Institut für Pharmakologie und Toxikologie, Universität Innsbruck, Austria.

The involvement of dopaminergic neurons of the hypothalamus in the modulation of histamine release was studied by the push-pull technique. The posterior hypothalamus of the conscious, freely moving rat was superfused with artificial cerebrospinal fluid (CSF) and the release of histamine was determined radioenzymatically in the superfusate. Agonists and antagonists of dopamine D1-, D2- and D3-receptors were dissolved in CSF and applied to the hypothalamus through the push-pull cannula. Hypothalamic superfusion with the D1-, D2- and D3-receptor agonists dopamine or R(-)-apomorphine enhanced the release rate of histamine. (+/-)-Apomorphine also enhanced the release of histamine, but to a lesser extent than did equimolar concentration of R(-)-apomorphine. The D3-agonist quinpirole inhibited the release of histamine, while the D1-receptor agonist SKF 82958 [(+-)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine] did not virtually influence the release of the neurotransmitter. On the other hand, [-]-sulpiride which predominantly blocks D2-receptors, decreased histamine release. Hypothalamic superfusion with SKF 83566 [(+-)-7-bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepine], which seems to be a selective antagonist of D1-receptors, enhanced the release rate of histamine. These findings suggest that dopaminergic neurons of the hypothalamus influence the release of histamine from its neurons in a dual way. D2-heteroreceptors stimulate the release of histamine, while D3-heteroreceptors seem to inhibit the release of this neurotransmitter. Both types of dopamine receptors might be located presynaptically on histaminergic neurons.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007031 Hypothalamus Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE. Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D008297 Male Males
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D006636 Histamine Release The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's Fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. Histamine Liberation,Histamine Liberations,Histamine Releases
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013469 Sulpiride A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed) Aiglonyl,Arminol,Deponerton,Desisulpid,Digton,Dogmatil,Dolmatil,Eglonyl,Ekilid,Guastil,Lebopride,Meresa,Pontiride,Psicocen,Sulp,Sulperide,Sulpitil,Sulpivert,Sulpor,Synédil,Tepavil,Vertigo-Meresa,neogama,vertigo-neogama,Vertigo Meresa,vertigo neogama
D015259 Dopamine Agents Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. Dopamine Drugs,Dopamine Effect,Dopamine Effects,Dopaminergic Agents,Dopaminergic Drugs,Dopaminergic Effect,Dopaminergic Effects,Agents, Dopamine,Agents, Dopaminergic,Drugs, Dopamine,Drugs, Dopaminergic,Effect, Dopamine,Effect, Dopaminergic,Effects, Dopamine,Effects, Dopaminergic
D015647 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine A selective D1 dopamine receptor agonist used primarily as a research tool. 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-,R-SK&F 38393,SK&F-38393,SKF 38393-A,SKF-38393,SKF38393,RSK&F 38393,SK&F 38393,SK&F38393,SKF 38393,SKF 38393 A,SKF 38393A
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

H Prast, and M Heistracher, and A Philippu
December 1994, Naunyn-Schmiedeberg's archives of pharmacology,
H Prast, and M Heistracher, and A Philippu
March 1997, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
H Prast, and M Heistracher, and A Philippu
March 1997, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
H Prast, and M Heistracher, and A Philippu
July 1990, Journal of neurochemistry,
H Prast, and M Heistracher, and A Philippu
July 1996, Scandinavian journal of gastroenterology,
H Prast, and M Heistracher, and A Philippu
November 1986, The Journal of pharmacology and experimental therapeutics,
H Prast, and M Heistracher, and A Philippu
March 1997, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
H Prast, and M Heistracher, and A Philippu
March 1997, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
H Prast, and M Heistracher, and A Philippu
April 2002, Biochemical pharmacology,
Copied contents to your clipboard!